Menu Back toSession-1-Innovative-Approaches-to-Paediatric-Drug-Development-State-of-Play-and-Possible-Impact

Better Medicines for Children, A DIA/EFGCP Conference

Plan ahead and join us to reflect on the importance of two major headways that are currently affecting Paediatric research: Innovative approaches to Drug Development and impact of the current environment on the Regulatory and Research Infrastructure


Session 1: Innovative Approaches to Paediatric Drug Development – State of Play and Possible Impact

Session Chair(s)

Martine  Dehlinger-Kremer, PhD

Martine Dehlinger-Kremer, PhD

  • Vice President, Pediatric Development
  • Synteract, United States
Session 1: Innovative Approaches to Paediatric Drug Development – State of Play and Possible Impact

Speaker(s)

Ralph  Bax, MD, PhD

EMA Regulatory Science Strategy 2025 - How Will It Impact Paediatric Development?

Ralph Bax, MD, PhD

  • Head of the Paediatric Medicines Office
  • European Medicines Agency, Netherlands
Dimitrios  Athanasiou, MBA

Panel Discussion

Dimitrios Athanasiou, MBA

  • Patient Advocate
  • WORLD DUCHENNE ORGANIZATION (WDO) , MDA HELLAS, Greece
Geneviève  Le Visage, PharmD, MSc

Panel Discussion

Geneviève Le Visage, PharmD, MSc

  • Regional Head RA Europe Policy & Liaison
  • Novartis Pharma AG, Switzerland
Siri  Wang, PhD

Panel Discussion

Siri Wang, PhD

  • Scientific Director; PDCO Member
  • Norwegian Medicines Agency, Norway

Contact us


Registration Questions?

Send Email
+41 61 225 51 51